CTRI/2019/07/020249招募中未知
To study the role of Liquid Based Cytology (LBC) for diagnosis and characterization of Biliopancreatic tumors compared with standard cytology and on-site evaluation-A non-inferiority trial.
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Consenting patients (or guardian) undergoing EUS guided sampling of suspected pancreato-biliary tumors
排除标准
- •1) Patients on anti-platelet agents(including aspirin).
- •2) Patients with deranged coagulation parameters, defined by platelet counts <75,000/mm3 and/or INR >1.8
研究者
相似试验
Unknown
不适用
To Study the Role of Liquid Based Cytology (LBC) for Diagnosis and Characterization of Biliopancreatic Tumor s Compared With Standard Cytology and On-site Evaluation.Pancreatobiliary-Type CarcinomaNCT04022408Institute of Liver and Biliary Sciences, India60
已完成
不适用
Effectiveness of Liquid Based Cytology (LBC) for Genetic Testing on Non-Small-Cell Lung CancerPrimary non-small-cell lung cancerJPRN-UMIN000016727Department of Thoracic Surgery, Kitasato University117
尚未招募
不适用
Comparison of Liquid Based Cytology with Conventional Pap Smear in the Detection of Cervical CancerCTRI/2022/02/040123Department of Obstetrics and Gynaecology
招募中
不适用
Role of liquid biopsy, analysis of circulating tumor cells and organoids in the diagnostic and therapy of upper-GI and hepato-pancreatico-bilary cancers (GI- and HPB-CA)C15C16C22C23C24C25Malignant neoplasm of oesophagusMalignant neoplasm of stomachMalignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of gallbladderMalignant neoplasm of other and unspecified parts of biliary tractMalignant neoplasm of pancreasDRKS00022375niversitätsklinik für innere Medizin - Gastroenterologie, Klinikum Oldenburg150
进行中（未招募）
1 期
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10025055Term: Lung cancer non-small cell stage IV Class: 10029104CTIS2024-511317-38-00Fundacion GECP33